Takashi Egawa

Fukuoka, Japan

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 21 publications

Zero Events, Limited Precision, and the Interpretation of Olanzapine Safety in Patients with Diabetes Receiving Cisplatin [Response to Letter].

Zero Events, Limited Precision, and the Interpretation of Olanzapine Safety in Patients with Diabetes Receiving Cisplatin [Response to Letter].

Journal: Drug design, development and therapy
Published: July 30, 2026

Pharmacy operations within the Japan Disaster Relief (JDR) medical team during the 2025 Myanmar Earthquake: Practices, challenges, and lessons learned.

Pharmacy operations within the Japan Disaster Relief (JDR) medical team during the 2025 Myanmar Earthquake: Practices, challenges, and lessons learned.

Journal: American journal of disaster medicine
Published: June 09, 2026

Navigating the Generosity of Medicines (Gen-MED): characterizing the complex relationships of medication donations in Japan through stakeholder and social network analysis.

Navigating the Generosity of Medicines (Gen-MED): characterizing the complex relationships of medication donations in Japan through stakeholder and social network analysis.

Journal: Frontiers in public health
Published: April 27, 2026

Safety of Short-T erm Low-Dose Olanzapine in Patients with Cancer and Diabetes Receiving Cisplatin-Based Chemotherapy: A Retrospective TriNetX Cohort Study.

Safety of Short-T erm Low-Dose Olanzapine in Patients with Cancer and Diabetes Receiving Cisplatin-Based Chemotherapy: A Retrospective TriNetX Cohort Study.

Journal: Drug design, development and therapy
Published: April 10, 2026

Clinical outcomes of daptomycin in patients with augmented renal clearance: a case series.

Clinical outcomes of daptomycin in patients with augmented renal clearance: a case series.

Journal: Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy
Published: March 13, 2026

Multiple-day dexamethasone for controlling delayed chemotherapy-induced nausea and vomiting with low-emetic-risk chemotherapy.

Multiple-day dexamethasone for controlling delayed chemotherapy-induced nausea and vomiting with low-emetic-risk chemotherapy.

Journal: BMC cancer
Published: October 17, 2025

Mannitol versus furosemide for prevention of cisplatin-induced nephrotoxicity in a multicenter retrospective cohort study.

Mannitol versus furosemide for prevention of cisplatin-induced nephrotoxicity in a multicenter retrospective cohort study.

Journal: Scientific reports
Published: May 29, 2025

Efficacy of 3-day versus 5-day aprepitant regimens for long-delayed chemotherapy-induced nausea and vomiting in patients receiving cisplatin-based chemotherapy.

Efficacy of 3-day versus 5-day aprepitant regimens for long-delayed chemotherapy-induced nausea and vomiting in patients receiving cisplatin-based chemotherapy.

Journal: Expert opinion on pharmacotherapy
Published: November 27, 2023

Comparison of preventive effects of combined furosemide and mannitol versus single diuretics, furosemide or mannitol, on cisplatin-induced nephrotoxicity.

Comparison of preventive effects of combined furosemide and mannitol versus single diuretics, furosemide or mannitol, on cisplatin-induced nephrotoxicity.

Journal: Scientific reports
Published: October 21, 2023

Adrenaline-resistant anaphylactic shock caused by contrast medium in a patient after risperidone overdose: a case report.

Adrenaline-resistant anaphylactic shock caused by contrast medium in a patient after risperidone overdose: a case report.

Journal: Journal of pharmaceutical health care and sciences
Published: March 24, 2023

Effectiveness of Palonosetron, 1-Day Dexamethasone, and Aprepitant in Patients Undergoing Carboplatin-Based Chemotherapy.

Effectiveness of Palonosetron, 1-Day Dexamethasone, and Aprepitant in Patients Undergoing Carboplatin-Based Chemotherapy.

Journal: Oncology
Published: January 27, 2023

Therapeutic effect of anti-HMGB1 antibody in a mouse model of 4-h middle cerebral artery occlusion: comparison with tissue plasminogen activator.

Therapeutic effect of anti-HMGB1 antibody in a mouse model of 4-h middle cerebral artery occlusion: comparison with tissue plasminogen activator.

Journal: Neuroreport
Published: May 20, 2022
Showing 1-12 of 21

Last Updated: 09/26/2026